These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 1666344)

  • 1. [A study of IL-2 activity on lung cancer].
    Wang YZ
    Zhonghua Jie He He Hu Xi Za Zhi; 1991 Aug; 14(4):216-8, 255. PubMed ID: 1666344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin (IL-)15 has less activity than IL-2 to promote type 2 cytokine predominance in tumour-associated mononuclear cells from lung cancer patients.
    Takeuchi E; Yanagawa H; Suzuki Y; Shinkawa K; Bando H; Sone S
    Cytokine; 2001 Jan; 13(2):119-23. PubMed ID: 11145853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
    Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
    Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer.
    Milman N; Pedersen LM
    Oncol Rep; 2002; 9(1):193-8. PubMed ID: 11748482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of VEGF-C, VEGF-D, and sVEGF-R2 in patients with lung cancer during chemotherapy.
    Naumnik W; Izycki T; Swidzińska E; Ossolińiska M; Chyczewska E
    Oncol Res; 2007; 16(9):445-51. PubMed ID: 18074680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-12-mediated killer activity in lung cancer patients.
    Haku T; Yanagawa H; Nabioullin R; Takeuchi E; Sone S
    Cytokine; 1997 Nov; 9(11):846-52. PubMed ID: 9367545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers and IL-2R in lung cancer.
    Marino P; Preatoni A; Fonticoli L; Parodi M; Tarolo GL
    Recenti Prog Med; 1990 Nov; 81(11):702-4. PubMed ID: 1962891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High plasma D-dimer level is associated with decreased survival in patients with lung cancer.
    Altiay G; Ciftci A; Demir M; Kocak Z; Sut N; Tabakoglu E; Hatipoglu ON; Caglar T
    Clin Oncol (R Coll Radiol); 2007 Sep; 19(7):494-8. PubMed ID: 17513096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum endostatin levels in patients with lung carcinoma.
    Swidzińska E; Ossolińska M; Naumnik W; Trojan S; Chyczewska E
    Rocz Akad Med Bialymst; 2005; 50():197-200. PubMed ID: 16358965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer.
    De Vita F; Orditura M; Auriemma A; Infusino S; Roscigno A; Catalano G
    Oncol Rep; 1998; 5(3):649-52. PubMed ID: 9538169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
    Li R; Li R; Wang Y
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutathione peroxidase, glutathione-S-transferase, catalase, xanthine oxidase, Cu-Zn superoxide dismutase activities, total glutathione, nitric oxide, and malondialdehyde levels in erythrocytes of patients with small cell and non-small cell lung cancer.
    Kaynar H; Meral M; Turhan H; Keles M; Celik G; Akcay F
    Cancer Lett; 2005 Sep; 227(2):133-9. PubMed ID: 16112416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated vascular endothelial growth factor levels in sera of patients with lung cancer.
    Takigawa N; Segawa Y; Fujimoto N; Hotta K; Eguchi K
    Anticancer Res; 1998; 18(2B):1251-4. PubMed ID: 9615796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of IL-6 level in serum and bronchoalveolar lavage fluid of patients with non-small cell lung cancer (NSCLC)].
    Huang F; Wang XL; Geng Y; Li MX
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Jul; 21(4):507-9. PubMed ID: 15989803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exogenous interleukin 2 regulates interleukin 6 and nitric oxide but not interferon gamma and tumor necrosis factor alpha production in bronchoalveolar leukocytes from patients with small cell lung cancer.
    Cembrzyńska-Nowak M; Bieńkowska M; Szklarz E
    Arch Immunol Ther Exp (Warsz); 1998; 46(6):367-74. PubMed ID: 9883316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
    Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
    Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer.
    Joensuu H; Anttonen A; Eriksson M; Mäkitaro R; Alfthan H; Kinnula V; Leppä S
    Cancer Res; 2002 Sep; 62(18):5210-7. PubMed ID: 12234986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cyfra 21-1--a new tumor marker of the cytokeratin series in differential diagnosis of lung diseases].
    Oremek GM; Seiffert UB; Siekmeier R; Kirsten R
    Med Klin (Munich); 1995 Jan; 90(1):23-6. PubMed ID: 7533887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
    Hartsell WF; Scott CB; Dundas GS; Mohiuddin M; Meredith RF; Rubin P; Weigensberg IJ
    Am J Clin Oncol; 2007 Aug; 30(4):368-76. PubMed ID: 17762437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.